Assessing How Consumers Interpret and Act on Results From At-Home COVID-19 Self-test Kits A Randomized Clinical Trial

被引:21
|
作者
Woloshin, Steven [1 ,2 ]
Dewitt, Barry [3 ,4 ]
Krishnamurti, Tamar [5 ]
Fischhoff, Baruch [3 ]
机构
[1] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Med Media, Lebanon, NH 03756 USA
[2] Lisa Schwartz Fdn Truth Med, Norwich, VT USA
[3] Carnegie Mellon Univ, Dept Engn & Publ Policy, Pittsburgh, PA 15213 USA
[4] Lund Univ, Dept Clin Sci, Med Eth, Lund, Scania, Sweden
[5] Univ Pittsburgh, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA
基金
美国医疗保健研究与质量局;
关键词
D O I
10.1001/jamainternmed.2021.8075
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE The US Food and Drug Administration (FDA) authorized SARS-CoV-2 rapid at-home self-test kits for individuals with and without symptoms. How appropriately users interpret and act on the results of at-home COVID-19 self-tests is unknown. OBJECTIVE To assess how users of at-home COVID-19 self-test kits interpret and act on results when given instructions authorized by the FDA, instructions based on decision science principles, or no instructions. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial was conducted of 360 adults in the US who were recruited in April 2021 to complete an online survey on their interpretation of at-home COVID-19 self-test results. Participants were given 1 of 3 instruction types and were presented with 1 of 4 risk scenarios. Participants were paid $5 and had a median survey completion time of 8.7 minutes. Data analyses were performed from June to July 2021. INTERVENTION Participants were randomized to receiving either the FDA-authorized instructions (authorized), the intervention instructions (intervention), or no instructions (control), and to 1 of 4 scenarios: 3 with a high pretest probability of infection (COVID-19 symptoms and/or a close contact with COVID-19) and 1 with low pretest probability (no symptoms and no contact). The intervention instructions were designed using decision science principles. MAIN OUTCOMES AND MEASURES Proportion of participants in the high pretest probability scenarios choosing to quarantine per federal recommendations and perceived probabilities of infection given a negative or positive COVID-19 test result. A Bonferroni correction accounted for multiple comparisons (3 instruction types x 4 scenarios; alpha = 0.004). RESULTS After excluding 22 individuals who completed the survey too quickly, the responses of 338 participants (median [IQR] age, 38 [31 to 48] years; 154 (46%) women; 215 (64%) with a college degree or higher) were included in the study analysis. Given a positive test result, 95%(322 of 338; 95% CI, 0.92 to 0.97) of the total participants appropriately chose to quarantine regardless of which instructions they had received. Given a negative test result, participants in the high pretest probability scenarios were more likely to fail to quarantine appropriately with the authorized instructions (33%) than with the intervention (14%; 95% CI for the 19% difference, 6% to 31%; P =.004) or control (24%; 95% CI for the 9% difference, -4% to 23%; P =.02). In the low pretest probability scenario, the proportion choosing unnecessary quarantine was higher with the authorized instructions (31%) than with the intervention (22%; 95% CI for the 9% difference, -14% to 31%) or control (10%; 95% CI for the 21% difference, 0.5% to 41%)-neither comparison was statistically significant (P =.05 and P =.20 respectively). CONCLUSIONS AND RELEVANCE The findings of this randomized clinical trial indicate that at-home COVID-19 self-test kit users relying on the authorized instructions may not follow the Centers for Disease Control and Prevention's quarantine recommendations, producing unintended risks and unnecessary disruptions. Redesigned instructions that follow decision science principles may improve compliance.
引用
收藏
页码:332 / 341
页数:10
相关论文
共 50 条
  • [21] Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial
    Weis, Nina
    Bollerup, Signe
    Sund, Jon Dissing
    Glamann, Jakob Borg
    Vinten, Caroline
    Jensen, Louise Riger
    Sejling, Christoffer
    Kledal, Thomas Nitschke
    Rosenkilde, Mette Marie
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (10) : 1313 - 1319
  • [22] Sedation with Sevoflurane versus Propofol in COVID-19 Patients with Acute Respiratory Distress Syndrome: Results from a Randomized Clinical Trial
    Martinez-Castro, Sara
    Monleon, Berta
    Puig, Jaume
    Ferrer Gomez, Carolina
    Quesada, Marta
    Pestana, David
    Balvis, Alberto
    Maseda, Emilio
    de la Rica, Alejandro Suarez
    Feijoo, Ana Monero
    Badenes, Rafael
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (06):
  • [23] Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial
    Forrest, Jamie, I
    Rawat, Angeli
    Duailibe, Felipe
    Guo, Christina M.
    Sprague, Sheila
    McKay, Paula
    Reis, Gilmar
    Mills, Edward J.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2022, 106 (02): : 389 - 393
  • [24] Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
    Gautret, Philippe
    Lagier, Jean-Christophe
    Parola, Philippe
    Van Thuan Hoang
    Meddeb, Line
    Mailhe, Morgane
    Doudier, Barbara
    Courjon, Johan
    Giordanengo, Valerie
    Vieira, Vera Esteves
    Dupont, Herve Tissot
    Honore, Stephane
    Colson, Philippe
    Chabriere, Eric
    La Scola, Bernard
    Rolain, Jean-Marc
    Brouqui, Philippe
    Raoult, Didier
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (01)
  • [25] Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited
    Gautret, Philippe
    Lagier, Jean-Christophe
    Honore, Stephane
    Van Thuan Hoang
    Colson, Philippe
    Raoult, Didier
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)
  • [26] Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial
    Di Pierro, Francesco
    Khan, Amjad
    Iqtadar, Somia
    Mumtaz, Sami Ullah
    Chaudhry, Muhammad Nabeel Akbar
    Bertuccioli, Alexander
    Derosa, Giuseppe
    Maffioli, Pamela
    Togni, Stefano
    Riva, Antonella
    Allegrini, Pietro
    Recchia, Martino
    Zerbinati, Nicola
    FRONTIERS IN PHARMACOLOGY, 2023, 13
  • [27] Targeting the Endothelium in the Treatment of COVID-19 Early Clinical Stages: Results of a Randomized Placebo-Controlled Trial
    Gonzalez-Ochoa, Alejandro
    BLOOD, 2021, 138
  • [28] Clinical and demographic differences in the willingness to use self-administered at-home COVID-19 testing measures among persons with opioid use disorder
    Mistler, Colleen B.
    Sullivan, Matthew
    Wickersham, Jeffrey A.
    Copenhaver, Michael M.
    Shrestha, Roman
    SUBSTANCE ABUSE, 2022, 43 (01) : 708 - 712
  • [29] A randomized controlled trial to test the effect of simplified guidance with visuals on comprehension of COVID-19 guidelines and intention to stay home if symptomatic
    Gold, Natalie
    Watson, Robin
    Weston, Dale
    Greaves, Felix
    Amlot, Richard
    BMC PUBLIC HEALTH, 2021, 21 (01)
  • [30] A randomized controlled trial to test the effect of simplified guidance with visuals on comprehension of COVID-19 guidelines and intention to stay home if symptomatic
    Natalie Gold
    Robin Watson
    Dale Weston
    Felix Greaves
    Richard Amlôt
    BMC Public Health, 21